ENDOSCOPIC GASTROPLASTY IN ROUTINE CLINICAL PRACTICE: PROSPECTIVE REGISTRY TRIAL

Aims The total number of bariatric endoscopic procedures is constantly increasing in routine clinical practice. Endoscopic gastroplasty (ESG) is safe and effective in patients with class I and II obesity associated with diet and lifestyle modifications. We present our results from a prospective clinical trial evaluating the role of the Endomina system (Endo Tools therapeutics, Belgium). The aim was to evaluate the mean total body weight loss (TBWL) and the mean excess weight loss (EWL) at 6 and 12 months.

Methods From July 2020 to May 2021 we enrolled in our Center 23 patients (19 female, 4 male) with class Body Mass Index 30–40 Kg/m2. ESG was performed under general anesthesia using CO2 insufflation. No procedure complications or device-related severe adverse events were observed and patients were discharged 24 hours following the procedure. All patients were followed for a total of 12 months after the ESG.

Results At 6 months mean%EWL was 62,56 and mean%TBWL was 16,89 with a higher mean quality of life (QoL) compared to that before the procedure. The 12 months follow-up after the endoscopic gastroplasty is still ongoing; from the 23 patients initially enrolled 12 completed the follow-up with good results. In fact at 12 months the mean EWL was 58,76% and the mean TBWL was 16,25%.

Conclusions In our clinical experience ESG in combination with diet and lifestyle modifications is a safe and effective option for patients with class I and II obesity. Further data on a larger sample of patients is needed.

Publication History

Article published online:
14 April 2022